Literature DB >> 25122558

Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis.

Daniel Heinrichs1, Marie-Luise Berres2, Melanie Coeuru3, Meike Knauel3, Andreas Nellen2, Petra Fischer2, Claudia Philippeit3, Richard Bucala4, Christian Trautwein2, Hermann E Wasmuth2, Jürgen Bernhagen5.   

Abstract

MIF is an inflammatory cytokine but is hepatoprotective in models of hepatotoxin-induced liver fibrosis. Hepatic fibrosis can also develop from metabolic liver disease, such as nonalcoholic fatty liver disease (NASH). We investigated the role of MIF in high-fat or methionine- and choline-deficient diet mouse models of NASH. Mif(-/-) mice showed elevated liver triglyceride levels (WT, 53±14 mg/g liver; Mif(-/-), 103±7 mg/g liver; P<0.05) and a 2-3-fold increased expression of lipogenic genes. Increased fatty degeneration in the livers of Mif(-/-) mice was associated with increased hepatic inflammatory cells (1.6-fold increase in F4/80(+) macrophages) and proinflammatory cytokines (e.g., 2.3-fold increase in Tnf-α and 2-fold increase in Il-6 expression). However, inflammatory cells and cytokines were decreased by 50-90% in white adipose tissue (WAT) of Mif(-/-) mice. Subset analysis showed that macrophage phenotypes in livers of Mif(-/-) mice were skewed toward M2 (e.g., 1.7-fold and 2.5-fold increase in Arg1 and Il-13, respectively, and 2.5-fold decrease in iNos), whereas macrophages were generally reduced in WAT of these mice (70% reduction in mRNA expression of F4/80(+) macrophages). The protective MIF effect was scrutinized in isolated hepatocytes. MIF reversed inflammation-induced triglyceride accumulation in Hepa1-6 cells and primary hepatocytes and also attenuated oleic acid-elicited triglyceride increase in 3T3-L1 adipocytes. Protection from fatty hepatocyte degeneration was paralleled by a 2- to 3-fold reduction by MIF of hepatocyte proinflammatory cytokine production. Blockade of MIF receptor cluster of differentiation 74 (CD74) but not of CXCR2 or CXCR4 fully reverted the protective effect of MIF, comparable to AMPK inhibition. In summary, we demonstrate that MIF mediates hepatoprotection through the CD74/AMPK pathway in hepatocytes in metabolic models of liver injury. © FASEB.

Entities:  

Keywords:  cytokines; fatty liver; hepatic fibrosis; hepatocyte; inflammation

Mesh:

Substances:

Year:  2014        PMID: 25122558      PMCID: PMC4232286          DOI: 10.1096/fj.14-256776

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  45 in total

1.  NASH-related liver failure: one hit too many?

Authors:  Christopher P Day
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

Review 3.  CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.

Authors:  Federica Borghese; Felix I L Clanchy
Journal:  Expert Opin Ther Targets       Date:  2011-01-06       Impact factor: 6.902

Review 4.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

5.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways.

Authors:  Ji Yeon Kim; Eun Hyun Song; Hyun Jung Lee; Yeo Kyoung Oh; Kyung-Hee Choi; Dae-Yeul Yu; Sang Ick Park; Je-Kyung Seong; Won-Ho Kim
Journal:  J Mol Biol       Date:  2010-02-13       Impact factor: 5.469

Review 7.  Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.

Authors:  Andreas Schäffler; Jürgen Schölmerich; Christa Büchler
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-06

Review 8.  Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Yurie Soejima; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

Review 9.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Authors:  Kenneth Cusi
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

Review 10.  The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis.

Authors:  Yaw Asare; Martin Schmitt; Jürgen Bernhagen
Journal:  Thromb Haemost       Date:  2013-01-17       Impact factor: 5.249

View more
  25 in total

Review 1.  The macrophage migration inhibitory factor protein superfamily in obesity and wound repair.

Authors:  Bong-Sung Kim; Norbert Pallua; Jürgen Bernhagen; Richard Bucala
Journal:  Exp Mol Med       Date:  2015-05-01       Impact factor: 8.718

2.  Macrophage Migration Inhibitory Factor Limits Renal Inflammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest.

Authors:  Sonja Djudjaj; Ina V Martin; Eva M Buhl; Nina J Nothofer; Lin Leng; Marta Piecychna; Jürgen Floege; Jürgen Bernhagen; Richard Bucala; Peter Boor
Journal:  J Am Soc Nephrol       Date:  2017-08-11       Impact factor: 10.121

Review 3.  Animal Models Correlating Immune Cells for the Development of NAFLD/NASH.

Authors:  Srikanth Iyer; Pramod Kumar Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  J Clin Exp Hepatol       Date:  2015-07-09

4.  Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients.

Authors:  Veronica Marin; Kyle Poulsen; Gemma Odena; Megan R McMullen; Jose Altamirano; Pau Sancho-Bru; Claudio Tiribelli; Juan Caballeria; Natalia Rosso; Ramon Bataller; Laura E Nagy
Journal:  J Hepatol       Date:  2017-06-22       Impact factor: 25.083

5.  Differential regulation of macrophage activation by the MIF cytokine superfamily members MIF and MIF-2 in adipose tissue during endotoxemia.

Authors:  Bong-Sung Kim; Pathricia V Tilstam; Kevin Arnke; Lin Leng; Tim Ruhl; Marta Piecychna; Wibke Schulte; Maor Sauler; Florian S Frueh; Gabriele Storti; Nicole Lindenblatt; Pietro Giovanoli; Norbert Pallua; Jürgen Bernhagen; Richard Bucala
Journal:  FASEB J       Date:  2020-01-21       Impact factor: 5.191

6.  MIF Matters: The Macrophage Migration Inhibitory Factor and Kidney Injury.

Authors:  Mark Unruh; Brent Wagner; Kenneth R Hallows
Journal:  Am J Kidney Dis       Date:  2018-09-18       Impact factor: 8.860

Review 7.  Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies.

Authors:  Martine C Morrison; Robert Kleemann
Journal:  Front Immunol       Date:  2015-06-15       Impact factor: 7.561

8.  Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis.

Authors:  Kyle L Poulsen; Xiude Fan; Christopher D Kibler; Emily Huang; Xiaoqin Wu; Megan R McMullen; Lin Leng; Richard Bucala; Meritxell Ventura-Cots; Josepmaria Argemi; Ramon Bataller; Laura E Nagy
Journal:  JCI Insight       Date:  2021-06-08

Review 9.  CD74 in Kidney Disease.

Authors:  Lara Valiño-Rivas; Ciro Baeza-Bermejillo; Laura Gonzalez-Lafuente; Ana Belen Sanz; Alberto Ortiz; Maria Dolores Sanchez-Niño
Journal:  Front Immunol       Date:  2015-09-23       Impact factor: 7.561

Review 10.  Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives.

Authors:  Lukas Pawig; Christina Klasen; Christian Weber; Jürgen Bernhagen; Heidi Noels
Journal:  Front Immunol       Date:  2015-08-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.